Pediatric Low Grade Glioma (LGG) Initiative

A phase II study of RAD001 (everolimus) for children with chemotherapy hemotherapy-refractory progressive symptomatic low grade gliomas

Principal Investigator: Mark W. Kieran, MD, PhD

Institute: Dana-Farber Cancer Institute

Initiative: Pediatric Low Grade Glioma (LGG) Initiative

Location: Boston, MA

Development of clinically relevant orthotopic xenograft mouse models of childhood low grade glioma from primary tumor tissues

Principal Investigator: Xiao-Nan Li, MD, PhD

Institute: Texas Children’s Cancer Center

Initiative: Pediatric Low Grade Glioma (LGG) Initiative

Location: Houston, TX

Establishment of a consortium-based tissue bank dedicated to Pediatric LGA

Principal Investigator: Charles D. Stiles, PhD

Institute: Dana-Farber Cancer Institute

Initiative: Pediatric Low Grade Glioma (LGG) Initiative

Location: Boston, MA

Identification of the molecular signature of progressive JPA

Principal Investigator: Elizabeth Maher, MD, PhD

Institute: Dana-Farber Cancer Institute

Initiative: Pediatric Low Grade Glioma (LGG) Initiative

Location: Boston, MA

Peptide vaccine based immunotherapy for pediatric low grade gliomas

Principal Investigator: Ian Pollack, MD

Institute: University of Pittsburgh

Initiative: Pediatric Low Grade Glioma (LGG) Initiative

Location: Pittsburgh, PA

Targeting the hedgehog pathway in pediatric low grade glioma

Principal Investigator: Michael K. Cooper, MD

Institute: Vanderbilt University Medical Center

Initiative: Pediatric Low Grade Glioma (LGG) Initiative

Location: Nashville, TN

Principal Investigator: Michael K. Cooper, MD

Institute: Vanderbilt University Medical Center

Initiative: Pediatric Low Grade Glioma (LGG) Initiative

Location: Nashville, TN

Share